Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third-line antidiabetic drugs in patients with type 2 diabetes.
about
Incidence of diabetes-related complications in Chinese patients with type 1 diabetes: a population-based longitudinal cohort study in Taiwan.Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study.Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea.Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
P2860
Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third-line antidiabetic drugs in patients with type 2 diabetes.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Comparative cardiovascular ris ...... patients with type 2 diabetes.
@en
Comparative cardiovascular ris ...... patients with type 2 diabetes.
@nl
type
label
Comparative cardiovascular ris ...... patients with type 2 diabetes.
@en
Comparative cardiovascular ris ...... patients with type 2 diabetes.
@nl
prefLabel
Comparative cardiovascular ris ...... patients with type 2 diabetes.
@en
Comparative cardiovascular ris ...... patients with type 2 diabetes.
@nl
P2093
P2860
P356
P1476
Comparative cardiovascular ris ...... patients with type 2 diabetes.
@en
P2093
Huang-Tz Ou
Jin-Shang Wu
Kai-Cheng Chang
P2860
P304
P356
10.1111/BCP.13241
P407
P50
P577
2017-01-21T00:00:00Z